Akums Drugs and Pharmaceuticals · NSE: AKUMS · BSE: 544222
Q1 FY25 results · Apr–Jun 2024
Akums Drugs and Pharmaceuticals reported revenue from operations of ₹1,019.11 crore and net profit of ₹61.21 crore for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,019.11 | — | — | — | — |
| Other income | 6.55 | — | — | — | — |
| Total income | 1,025.66 | — | — | — | — |
| Profit before tax | 87.48 | — | — | — | — |
| Net profit for the period | 61.21 | — | — | — | — |
| Attributable to shareholders of the company | 60.17 | — | — | — | — |
| EPS, basic (₹) | 4.21 | — | — | — | — |
| Net margin (%) | 6.0 | — | — |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 317.27 | — | — | — | — |
| Other income | 26.18 | — | — | — | — |
| Total income | 343.45 | — | — | — | — |
| Profit before tax | 54.27 | — | — | — | — |
| Net profit for the period | 41.88 | — | — | — | — |
| EPS, basic (₹) | 2.93 | — | — | — | — |
| Net margin (%) | 13.2 | — | — |
Consolidated
- Filed with BSE
- 30 Aug 2024, 13:21 IST
- Board meeting
- 24 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Aug 2024, 13:21 IST
- Board meeting
- 24 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE